ATE458469T3 - Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit - Google Patents

Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit Download PDF

Info

Publication number
ATE458469T3
ATE458469T3 AT05010806T AT05010806T ATE458469T3 AT E458469 T3 ATE458469 T3 AT E458469T3 AT 05010806 T AT05010806 T AT 05010806T AT 05010806 T AT05010806 T AT 05010806T AT E458469 T3 ATE458469 T3 AT E458469T3
Authority
AT
Austria
Prior art keywords
present
directed
patient
flowable composition
implant
Prior art date
Application number
AT05010806T
Other languages
English (en)
Inventor
Richard Dunn
John S Garrett
Harish Ravivarapu
Bhagya L Chandrashekar
Original Assignee
Qlt Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27099398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458469(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Qlt Usa Inc filed Critical Qlt Usa Inc
Publication of ATE458469T3 publication Critical patent/ATE458469T3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3205—Separate rigid or semi-rigid containers joined to each other at their external surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AT05010806T 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit ATE458469T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66617400A 2000-09-21 2000-09-21
US09/711,758 US6565874B1 (en) 1998-10-28 2000-11-13 Polymeric delivery formulations of leuprolide with improved efficacy

Publications (1)

Publication Number Publication Date
ATE458469T3 true ATE458469T3 (de) 2010-03-15

Family

ID=27099398

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01973341T ATE296088T3 (de) 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit
AT05010806T ATE458469T3 (de) 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01973341T ATE296088T3 (de) 2000-09-21 2001-09-21 Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit

Country Status (27)

Country Link
US (8) US6565874B1 (de)
EP (3) EP1322286B3 (de)
JP (4) JP2004510807A (de)
KR (1) KR100831113B1 (de)
CN (2) CN101669900B (de)
AT (2) ATE296088T3 (de)
AU (4) AU9293101A (de)
BR (1) BRPI0114069B8 (de)
CA (1) CA2436275C (de)
CY (3) CY1106045T1 (de)
CZ (1) CZ303134B6 (de)
DE (2) DE60141421D1 (de)
DK (3) DK1322286T6 (de)
ES (3) ES2341777T7 (de)
HK (2) HK1139596A1 (de)
HU (1) HU228386B1 (de)
IL (2) IL155006A0 (de)
IS (1) IS6794A (de)
MX (1) MXPA03002552A (de)
NZ (1) NZ525210A (de)
PL (1) PL226346B1 (de)
PT (3) PT2158900E (de)
RU (1) RU2271826C2 (de)
SI (1) SI1322286T1 (de)
SK (1) SK287528B6 (de)
WO (1) WO2002030393A2 (de)
ZA (1) ZA200302944B (de)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
AU2001276733A1 (en) * 2000-08-07 2002-02-18 Takeda Chemical Industries Ltd. Lactic acid polymer and process for producing the same
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
ES2372978T3 (es) 2002-06-07 2012-01-30 Dyax Corp. Polipéptido con dominio de kunitz modificado.
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
EP1622540A4 (de) * 2003-03-11 2009-12-30 Qlt Usa Inc Formulierungen für zellen-plan-abhängige krebsmittel
MXPA05009626A (es) * 2003-03-14 2005-10-18 Debio Rech Pharma Sa Sistema de liberacion subcutanea, su proceso de preparacion y uso para el tratamiento de trastornos de deficiencia colinergica.
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
US20040247672A1 (en) * 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005067960A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
CA2552757A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
WO2005067890A2 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
TW200538148A (en) * 2004-01-13 2005-12-01 Vasogenix Pharmaceuticals Inc Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
BRPI0506983A (pt) 2004-01-20 2007-07-03 Allergan Inc composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
US7829105B2 (en) * 2004-03-02 2010-11-09 Nanotherapeutics, Inc. Compositions for repairing bone
US8729202B2 (en) * 2004-03-03 2014-05-20 Polynovo Biomaterials Pty Limited Biocompatible polymer compositions for dual or multi staged curing
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1773350B1 (de) * 2004-07-12 2013-05-29 Allergan, Inc. Ophthalmische zusammensetzungen zur behandlung von augenleiden
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
CA2590696A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US20060189958A1 (en) * 2005-02-21 2006-08-24 Talton James D Inverted cannula for use in reconstituting dry material in syringes
KR101072239B1 (ko) * 2005-06-07 2011-10-12 생-고뱅 세라믹스 앤드 플라스틱스, 인코포레이티드 촉매 캐리어
WO2007011340A1 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
JP2009504269A (ja) 2005-08-08 2009-02-05 サイティック コーポレーション 膨張させて皮膚の間隔をとる方法
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080210748A1 (en) * 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
WO2007082726A2 (de) * 2006-01-17 2007-07-26 Medigene Ag Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
EP1988920A1 (de) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Verfahren zur behandlung von fettsucht durch verabreichung eines trkb-antagonisten
CA2651793C (en) 2006-02-02 2015-07-07 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
US8013061B2 (en) * 2006-03-08 2011-09-06 The University Of North Carolina At Chapel Hill Polyester based degradable materials and implantable biomedical articles formed therefrom
CN101511380B (zh) 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
US8076448B2 (en) * 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
BRPI0718696A2 (pt) * 2006-11-09 2013-12-31 Alcon Res Ltd Matriz de polímero insolúvel em água para liberação de fármaco.
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
TWI397426B (zh) * 2006-11-09 2013-06-01 Alcon Res Ltd 包含水不溶性聚合基質之淚點栓塞物
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7975699B2 (en) 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
ES2755374T3 (es) 2007-02-15 2020-04-22 Tolmar Therapeutics Inc Poli(lactida/glicolida) de descarga lenta y métodos para producir polímeros
BRPI0809995A2 (pt) * 2007-04-03 2015-07-21 Trimeris Inc Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
US10010612B2 (en) * 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
AU2008303896A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US20090112193A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices that utilize photolyzable nitric oxide donors
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US7846400B2 (en) * 2007-10-30 2010-12-07 The Invention Science Fund I, Llc Substrates for nitric oxide releasing devices
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8828354B2 (en) 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090264478A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Sulfasalazine formulations in a biodegradable polymer carrier
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
ES2569556T3 (es) 2008-06-03 2016-05-11 Indivior Uk Limited Complejo de inclusión de hidrogel deshidratado de un agente bioactivo con sistema fluido de administración de medicamento
CA2726763A1 (en) * 2008-06-03 2009-12-10 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
SI2291174T1 (sl) * 2008-06-03 2015-05-29 Tolmar Therapeutics, Inc. Tekoči sestavek, ki vsebuje biokompatibilne sestavke oligomer-polimer
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
CN101653422B (zh) * 2008-08-20 2013-03-20 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US9161903B2 (en) 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
US8469779B1 (en) 2009-01-02 2013-06-25 Lifecell Corporation Method for debristling animal skin
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8653029B2 (en) 2009-07-30 2014-02-18 Warsaw Orthopedic, Inc. Flowable paste and putty bone void filler
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8758791B2 (en) * 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US8475824B2 (en) * 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot preparation
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US9301946B2 (en) 2010-12-03 2016-04-05 Warsaw Orthopedic, Inc. Clonidine and GABA compounds in a biodegradable polymer carrier
US8623396B2 (en) 2010-12-03 2014-01-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
PL2658525T3 (pl) 2010-12-29 2018-02-28 Medincell Biodegradowalne kompozycje do dostarczania leków
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US8637067B1 (en) 2011-03-10 2014-01-28 Lifecell Corporation Elastic tissue matrix derived hydrogel
WO2012142419A1 (en) 2011-04-14 2012-10-18 Lifecell Corporation Regenerative materials
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9089523B2 (en) 2011-07-28 2015-07-28 Lifecell Corporation Natural tissue scaffolds as tissue fillers
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
DK3501558T3 (da) 2011-12-20 2021-03-01 Lifecell Corp Flydbare vævsprodukter
EP2793964B1 (de) 2011-12-20 2019-03-20 LifeCell Corporation Blattförmige tissueprodukte
BR112014018047B1 (pt) 2012-01-24 2019-11-26 Lifecell Corp composição de tratamento de tecido
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
CA2871665A1 (en) 2012-04-24 2013-10-31 Lifecell Corporation Flowable tissue matrices
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
AU2013289045B2 (en) 2012-07-13 2017-02-16 Lifecell Corporation Methods for improved treatment of adipose tissue
EP3332816B1 (de) 2012-09-26 2020-11-04 LifeCell Corporation Verarbeitetes fettgewebe
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
US9592254B2 (en) 2013-02-06 2017-03-14 Lifecell Corporation Methods for localized modification of tissue products
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
CA2965895C (en) 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
CN107920988B (zh) * 2015-08-03 2021-08-17 托尔玛国际有限公司 用于延长给药的液体聚合物递送系统
SG11201804037XA (en) 2015-11-16 2018-06-28 Evonik Roehm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
DK3377041T3 (da) 2015-11-16 2023-12-18 Medincell S A Fremgangsmåde til fragmentering og/eller målretning af farmaceutisk aktive bestanddele til synovialvæv
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
WO2017210109A1 (en) 2016-06-03 2017-12-07 Lifecell Corporation Methods for localized modification of tissue products
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
US10497172B2 (en) * 2016-12-01 2019-12-03 Pinscreen, Inc. Photorealistic facial texture inference using deep neural networks
AU2017382173A1 (en) 2016-12-22 2019-06-06 Lifecell Corporation Devices and methods for tissue cryomilling
CN110234336A (zh) * 2017-01-31 2019-09-13 维鲁公司 用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
KR102412628B1 (ko) * 2017-08-28 2022-06-23 차의과학대학교 산학협력단 전기분무 기술을 이용한 루프롤라이드 함유 서방성 미립구의 제조방법
RU2746566C2 (ru) * 2017-09-27 2021-04-15 Новел Фарма Инк. КОНЪЮГИРОВАННОЕ С ПАЛЬМИТИНОВОЙ КИСЛОТОЙ ПРОИЗВОДНОЕ GnRH ПРОЛОНГИРОВАННОГО ДЕЙСТВИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕГО
US11123375B2 (en) 2017-10-18 2021-09-21 Lifecell Corporation Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
CN115252910A (zh) 2017-10-18 2022-11-01 生命细胞公司 脂肪组织产品以及产生方法
ES2960617T3 (es) 2017-10-19 2024-03-05 Lifecell Corp Productos de matriz de tejido acelular fluida y métodos de producción
US11246994B2 (en) 2017-10-19 2022-02-15 Lifecell Corporation Methods for introduction of flowable acellular tissue matrix products into a hand
CA3084339A1 (en) * 2017-12-18 2019-06-27 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions having a selected release duration
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
UY38386A (es) * 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
US20200330547A1 (en) * 2019-04-22 2020-10-22 Tolmar International Limited Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition
EA202193257A1 (ru) 2019-05-27 2022-03-10 Толмар Интернэшнл Лимитед Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы
JP2022534110A (ja) 2019-05-30 2022-07-27 ライフセル コーポレーション 生物学的乳房インプラント
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
CA3180468A1 (en) 2020-06-30 2022-01-06 Jin Young Ko Injectable composition comprising gnrh analogue
WO2022069996A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US11908233B2 (en) 2020-11-02 2024-02-20 Pinscreen, Inc. Normalization of facial images using deep neural networks
EP4135830A1 (de) 2020-12-23 2023-02-22 Tolmar International Limited Systeme und verfahren zum mischen von spritzenventilanordnungen
KR102386163B1 (ko) 2021-12-03 2022-04-14 (주)인벤티지랩 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284417A (en) * 1963-11-13 1966-11-08 Union Carbide Corp Process for the preparation of lactone polyesters
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4040420A (en) * 1976-04-22 1977-08-09 General Dynamics Packaging and dispensing kit
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP2988633B2 (ja) 1990-03-16 1999-12-13 三和生薬株式会社 発毛・育毛剤
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP1125577B1 (de) 1994-04-08 2006-02-15 QLT USA, Inc. Flüssige Zusammensetzungen zur Arzneistoffabgabe
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747637A (en) 1995-09-07 1998-05-05 Mitsui Toatsu Chemicals, Inc. Bioabsorbable polymer and process for preparing the same
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
PL189137B1 (pl) * 1996-02-02 2005-06-30 Alza Corp Implantowane urządzenie do dostarczania substancji aktywnej
CA2275525C (en) * 1996-12-20 2011-02-08 Kevin J. Brodbeck Gel composition and methods
JPH10279499A (ja) * 1997-04-04 1998-10-20 Takeda Chem Ind Ltd 子宮粘膜適用製剤
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
KR100321854B1 (ko) 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
CN1146613C (zh) 1999-09-10 2004-04-21 三井化学株式会社 可降解的聚氨酯树脂
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US20070117959A1 (en) 2003-12-15 2007-05-24 The Children's Hospital Of Philadelphia Novel polyesters

Also Published As

Publication number Publication date
PL361671A1 (en) 2004-10-04
US9254307B2 (en) 2016-02-09
CN100536922C (zh) 2009-09-09
US20030133964A1 (en) 2003-07-17
DE60111068D1 (de) 2005-06-30
MXPA03002552A (es) 2005-09-08
DK1586309T6 (da) 2019-10-07
KR20030064401A (ko) 2003-07-31
US20160106805A1 (en) 2016-04-21
BR0114069A (pt) 2004-02-10
HK1141459A1 (en) 2010-11-12
EP1322286B1 (de) 2005-05-25
CN101669900B (zh) 2013-07-24
BRPI0114069B1 (pt) 2016-08-23
AU9293101A (en) 2002-04-22
PT1322286E (pt) 2005-08-31
JP2012012418A (ja) 2012-01-19
PT1586309E (pt) 2010-05-28
AU2010201645B2 (en) 2012-07-12
US20100234305A1 (en) 2010-09-16
US20040229912A1 (en) 2004-11-18
ES2241876T3 (es) 2005-11-01
US20100226954A1 (en) 2010-09-09
ES2241876T7 (es) 2018-02-16
WO2002030393A2 (en) 2002-04-18
CZ20031124A3 (cs) 2003-12-17
PT2158900E (pt) 2013-03-11
AU2010201645A1 (en) 2010-05-20
EP2158900A1 (de) 2010-03-03
IL155006A0 (en) 2003-10-31
ATE296088T3 (de) 2005-06-15
CA2436275A1 (en) 2002-04-18
US8486455B2 (en) 2013-07-16
AU2006241376A1 (en) 2006-12-14
PL226346B1 (pl) 2017-07-31
EP1586309B3 (de) 2019-09-18
IS6794A (is) 2003-04-23
JP2014240439A (ja) 2014-12-25
US6773714B2 (en) 2004-08-10
EP1322286B3 (de) 2017-08-16
DK1586309T3 (da) 2010-06-14
DK1322286T6 (da) 2017-11-13
JP2004510807A (ja) 2004-04-08
JP2013253101A (ja) 2013-12-19
HK1139596A1 (en) 2010-09-24
DK2158900T3 (da) 2013-02-18
WO2002030393A3 (en) 2002-06-27
KR100831113B1 (ko) 2008-05-20
EP1586309A1 (de) 2005-10-19
JP6061823B2 (ja) 2017-01-18
CA2436275C (en) 2007-01-02
ES2341777T7 (es) 2020-05-08
AU2006241376B2 (en) 2010-02-04
NZ525210A (en) 2004-10-29
CZ303134B6 (cs) 2012-04-25
US20070104759A1 (en) 2007-05-10
ZA200302944B (en) 2004-08-24
DK1322286T3 (da) 2005-08-01
CN1474685A (zh) 2004-02-11
US6565874B1 (en) 2003-05-20
DE60111068T3 (de) 2018-01-04
BRPI0114069B8 (pt) 2021-05-25
ES2341777T3 (es) 2010-06-28
HU228386B1 (hu) 2013-03-28
JP6087886B2 (ja) 2017-03-01
SK287528B6 (sk) 2011-01-04
HUP0302981A2 (hu) 2004-01-28
SK5152003A3 (en) 2003-10-07
DE60141421D1 (de) 2010-04-08
EP2158900B1 (de) 2013-01-23
EP1322286A2 (de) 2003-07-02
EP1586309B1 (de) 2010-02-24
IL155006A (en) 2007-06-03
CY1106045T1 (el) 2011-04-06
DE60111068T2 (de) 2006-01-26
AU2001292931B2 (en) 2006-08-24
CN101669900A (zh) 2010-03-17
HUP0302981A3 (en) 2006-07-28
SI1322286T1 (en) 2005-10-31
CY1110653T1 (el) 2015-06-10
CY1113920T1 (el) 2016-07-27
RU2271826C2 (ru) 2006-03-20
ES2404559T3 (es) 2013-05-28
JP5969190B2 (ja) 2016-08-17
US20150150937A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
ATE458469T3 (de) Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit
ATE209907T1 (de) Flüssige mittel zur wirkstoffabgabe
DE69925461D1 (de) Zielgerichtete abgabe von biologische-aktive medien
PT774964E (pt) Entrega local controlada de agentes quimioterapeuticos para tratamento de tumores solidos
FI20001696A (fi) Biologisesti aktiivinen materiaali
ES2114901T3 (es) Compuesto polimerico biodegradable.
WO2004069335A8 (en) Magnetic implants to treat body tissue structures
DE69333658D1 (de) Verfahren zur behandlung von organen und gewebe
WO2002011696A3 (en) Active tissue augmentation materials and method
JPH02152469A (ja) 薬剤カプセル
BRPI0117343B8 (pt) composição fluida para uso como um implante de liberação controlada, processo para formação da mesma, uso, kit e implante sólido
WO2021107752A1 (es) Tinta para tatuajes temporales y proceso para elaborarla
DeRoberts et al. Intense Pulsed Light Tattoo Removal in Conjunction with Imiquimod (Aldaraо): A Double-Blind, Randomized Controlled Study
EP1053753A1 (de) Lokaler Wirkstoffträger
ITBO990111A1 (it) Prodotto , metodo ed uso di poliacrilammide come veicolo per sostanzefarmacologiche .

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1586309

Country of ref document: EP